APACHE score
Citation, DOI, disclosures and article data
At the time the article was created Hamish Smith had no recorded disclosures.
View Hamish Smith's current disclosuresAt the time the article was last revised Henry Knipe had the following disclosures:
- Micro-X Ltd, Shareholder (past)
These were assessed during peer review and were determined to not be relevant to the changes that were made.
View Henry Knipe's current disclosures- APACHE score
- APACHE II score
- APACHE IV score
- APACHE III score
The Acute Physiology and Chronic Health Evaluation (APACHE) score is an illness severity score commonly used in critical care medicine to predict mortality upon admission to an intensive care unit.
On this page:
Usage
Although designed to calculate mortality in an intensive care unit, the APACHE score has a high sensitivity for predicting complications of acute pancreatitis, such as pancreatic necrosis and organ failure 3.The fourth iteration - APACHE IV - was published in 2006 4; however, the APACHE II score is still frequently used (c. 2023) 5.
Classification
APACHE II
It involves two sections - one assessing the severity of the acute illness and another assessing a patient's pre-illness chronic medical status. The worst values the patient achieves in the first 24 hours of admission to the intensive care unit should be used 2.
The following criteria are used in the calculation of the APACHE II score 2:
past history of organ failure or immunocompromised state (e.g. NYHA Class IV heart failure, cirrhosis, CKD requiring dialysis)
acute kidney injury
age
temperature
mean arterial pressure
blood pH
heart rate
respiratory rate
sodium
potassium
creatinine
hematocrit
white blood cell count
-
blood oxygenation
A-a gradient (if FiO2 is greater than or equal to 0.5)
PaO2 (if FiO2 is less than 0.5)
ADVERTISEMENT: Supporters see fewer/no ads
History and etymology
The APACHE score was first developed in 1981 by the American intensivist William Knaus and his colleagues 1. It was revised in 1985 to become the APACHE II score 2.
References
- 1. Knaus W, Zimmerman J, Wagner D, Draper E, Lawrence D. APACHE-Acute Physiology and Chronic Health Evaluation: A Physiologically Based Classification System. Crit Care Med. 1981;9(8):591-7. doi:10.1097/00003246-198108000-00008 - Pubmed
- 2. Knaus W, Draper E, Wagner D, Zimmerman J. APACHE II: A Severity of Disease Classification System. Crit Care Med. 1985;13(10):818-29. - Pubmed
- 3. Harshit Kumar A & Singh Griwan M. A Comparison of APACHE II, BISAP, Ranson’s Score and Modified CTSI in Predicting the Severity of Acute Pancreatitis Based on the 2012 Revised Atlanta Classification. Gastroenterol Rep. 2017;6(2):127-31. doi:10.1093/gastro/gox029 - Pubmed
- 4. Quintairos A, Pilcher D, Salluh J. ICU Scoring Systems. Intensive Care Med. 2023;49(2):223-5. doi:10.1007/s00134-022-06914-8 - Pubmed
- 5. Mumtaz H, Ejaz M, Tayyab M et al. APACHE Scoring as an Indicator of Mortality Rate in ICU Patients: A Cohort Study. Ann Med Surg (Lond). 2023;85(3):416-21. doi:10.1097/MS9.0000000000000264 - Pubmed
Incoming Links
Related articles: Pathology: Hepato-Pancreato-Biliary
- liver
- depositional disorders
- infection and inflammation
- liver abscess
- hepatic hydatid infection
- cirrhosis
- hepatitis
- cholecystitis
- cholangitis
- malignancy
- liver and intrahepatic bile duct tumors
- benign epithelial tumors
- hepatocellular hyperplasia
- hepatocellular adenoma
- hepatic/biliary cysts
- benign nonepithelial tumors
- primary malignant epithelial tumors
- hepatocellular carcinoma
- hepatocellular carcinoma variants
-
cholangiocarcinoma
- intra-hepatic
- mass-forming type
- periductal infiltrating type - Klatskin tumors
- intraductal growing type
- extra-hepatic/large duct type
- intra-hepatic
- biliary cystadenocarcinoma
- combined hepatocellular and cholangiocarcinoma
- hepatoblastoma
- undifferentiated carcinoma
- primary malignant nonepithelial tumors
- hematopoietic and lymphoid tumors
- primary hepatic lymphoma
- hepatic myeloid sarcoma (hepatic chloroma)
- secondary tumors
- miscellaneous
- adrenal rest tumors
- hepatic carcinosarcoma
- hepatic fibroma
- hepatic hemangioma
- hepatic Kaposi sarcoma
- hepatic lipoma
- hepatic mesenchymal hamartoma
- hepatic myxoma
- hepatic rhabdoid tumor
- hepatic solitary fibrous tumor
- hepatic teratoma
- hepatic yolk sac tumor
- inflammatory myofibroblastic tumor (inflammatory pseudotumor)
- nodular regenerative hyperplasia
- pancreatic rest tumors
- primary hepatic carcinoid
- benign epithelial tumors
- liver and intrahepatic bile duct tumors
- metabolic
- trauma
-
vascular and perfusion disorders
- portal vein related
- hepatic artery related
- hepatic veins related
- inferior vena cava related
- other
- third inflow
- liver thrombotic angiitis
- infra diaphragmatic total anomalous pulmonary venous return (TAPVR)
- hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease)
- pancreas
-
pancreatic neoplasms
- cystic neoplasm (cystic pancreatic mass differential diagnosis)
- solid neoplasm
- non-epithelial pancreatic neoplasms
- others
- simple pancreatic cyst
-
pancreatitis (mnemonic for the causes)
- acute pancreatitis
- chronic pancreatitis
- Ascaris-induced pancreatitis
- tropical pancreatitis
- autoimmune pancreatitis
- emphysematous pancreatitis
- hypertriglyceridemia-induced pancreatitis
- hereditary pancreatitis
- pancreatitis associated with cystic fibrosis
- pancreaticopleural fistula
- segmental pancreatitis
- pancreatic atrophy
- pancreatic lipomatosis
- pancreatic trauma
- pancreatic transplant
-
pancreatic neoplasms
- gallbladder and biliary
- congenital malformations and anatomical variants
- gallstones
- gallbladder inflammation
- bile ducts inflammation
- gallbladder wall abnormalities
- other gallbladder abnormalities
- bile duct dilatation (differential)
- bile duct wall thickening (differential)
- bile ducts neoplasms